Ivarmacitinib for the Treatment of Adults with Severe Alopecia Areata: Results from a Phase 3 Trial
1. 系统已在2025-09-30 16:50:20对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接: https://pubmed.mylibs.cn/40976531/
其他信息:
C Zhou, C Yang, W Fan, J Wu, D Yang, H Jin…
Journal of the American …, 2025
Elsevier
ABSTRACT Background Ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, demonstrated efficacy in a phase 2 trial for moderate-to-severe alopecia areata (AA). Objective To evaluate the efficacy and safety of ivarmacitinib in adults with severe AA (≥ 50% scalp hair loss, including alopecia totalis/universalis). Methods In this randomized, double-blind, phase 3 trial, 330 patients were assigned (1: 1: 1) to ivarmacitinib 4 mg, 8 mg, or placebo once daily for 24 weeks. Placebo recipients were re-randomized to ivarmacitinib …
